TITLE

Insulin spray will eliminate needles

PUB. DATE
September 2000
SOURCE
Hudson Valley Business Journal;09/25/2000-10/09/2000, Vol. 11 Issue 16, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports that Eli Lilly and Co. has signed an agreement with Generex Biotechnology Corp. to develop insulin that is administered as a fine spray into the mouth.
ACCESSION #
3631327

 

Related Articles

  • GENEREX AWARDED TWO NEW PATENTS FOR BUCCAL DRUG DELIVERY.  // Biotech Business;Jul2010, Vol. 23 Issue 7, p7 

    The article reports that Generex Biotechnology Corporation was awarded patents in Japan and Ukraine. According to Rose C. Perri, the company's chief operating officer, each patent issuance suggests the inventiveness of the company's buccal drug delivery platform technologies. Generex is based in...

  • INSULINS.  // Monthly Prescribing Reference;Mar2014, Vol. 30 Issue 3, p81 

    A table is presented which lists several insulin injections and drugs including the Insulin Injection Regular (R) from Eli Lilly & Co., the Insulin Lispro from Eli Lilly & Co. and the Insulin Glulisine from Sanofi-Aventis SA along with their brand names, route and duration.

  • Generex Biotechnology: vaccines a clear way ahead for RapidMist.  // PharmaWatch: Biotechnology;September 2004, Vol. 3 Issue 9, p6 

    Reports on the innovation made by Generex Biotechnology Corp. for the RapidMist platform technology for vaccine delivery. Uncertain profitability of the delivery system; Discussion of the prospects for Generex's RapidMist delivery system during the Foundation Merieux Conference in 2004.

  • GENEREX BIOTECHNOLOGY AWARDED NEW DRUG DELIVERY PATENT.  // Worldwide Biotech;Dec2008, Vol. 20 Issue 12, p1 

    The article reports on a drug delivery patent received by Generex Biotechnology Corp., a leading provider of drug delivery for metabolic diseases through the inner lining of the mouth, in Australia. A patent titled Micellar Pharmaceutical Compositions for Buccal and Pulmonary Application has...

  • Generex Biotechnology: vaccines a clear way ahead for RapidMist.  // PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p50 

    Reports on chief scientific officer of Generex Biotechnology's Antigen Express immunomedicines subsidiary, Robert Humphreys' presentation of a research abstract at the Foundation Merieux Conference discussing the prospects for the company's RapidMist delivery system. Benefits of the technology...

  • Gum to replace needles?  // Pharmaceutical Technology Europe;Feb2006, Vol. 18 Issue 2, p10 

    The article reports on Generex's development of a chewing gum as an alternative buccal drug delivery method for metformin, which is used for treating diabetes. Results from a small clinical trial suggest that the use of chewing gum could prevent gastrointestinal side-effects which usually...

  • Pharma: Clinic Roundup.  // BioWorld Today;6/13/2012, Vol. 23 Issue 114, p8 

    The article presents the results from two Phase II studies of the investigational basal insulin analogue LY2605541 of Eli Lilly and Co. and Boehringer Ingelheim GmbH.

  • Lilly moving forward with inhaled insulin. Adams, Brent // Indianapolis Business Journal;8/16/2004, Vol. 25 Issue 23, p43 

    Reports on Eli Lilly & Co.'s plans to proceed with the development of an insulin inhaler for the treatment of diabetes following the completion of a phase 2 clinical trial.

  • Eli Lilly, Dura Developing an Inhalable Insulin. Smith, Nevada // San Diego Business Journal;10/05/98, Vol. 19 Issue 40, p4 

    Reports on the agreement between Eli Lilly and Co. and Dura Pharmaceuticals to develop an insulin product based on the latter's proprietary pulmonary drug, an asthma inhaler known as Albuterol Spiros. Formulation of Dura's Spiros pulmonary system; Terms of the agreement; Licensing of the Spiros...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics